Lilly Bets on Chronic Inflammation With $1.2B All-Cash Acquisition of Ventyx

Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on...

January 11, 2026 | Sunday | News
Etienna Bio Secures Exclusive Global License From UMass Chan for Adipose-Derived Cell and Matrix Platform

Etienna Bio, Inc., a biotechnology company focused on next-generation autologous and cell-enabled biomaterials for regenerative and aesthetic application...

January 12, 2026 | Monday | News
Codexis and Axolabs Partner to Evaluate Enzymatic RNA Manufacturing Platform

Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing and Axolabs, part of LGC Gr...

January 12, 2026 | Monday | News
Shilpa Medicare’s OERIS™ Clears Phase 3, Showing Superior Convenience, Efficacy and Safety in CINV

Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondans...

January 12, 2026 | Monday | News
PathAI Collaborates With University Hospital Zurich to Deploy AI-Based Tumor Cell Quantification

PathAI, a global leader in AI-powered pathology, announced a strategic collaboration with University Hospital Zurich (USZ) to deploy AISight® Dx1, Pa...

January 09, 2026 | Friday | News
Lonza Licenses Clinically Validated ADC Platform to Sidewinder to Accelerate Bispecific Oncology Pipeline

  Multi-target license agreement grants Sidewinder access to Lonza's clinically validated ADC platform Sidewinder's ...

January 08, 2026 | Thursday | News
Nucleome Therapeutics Nominates First-in-Class Monoclonal Antibody Programme Targeting Inflammation Resolution

First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases...

January 08, 2026 | Thursday | News
Amgen Acquires Dark Blue Therapeutics To Advance DBT 3757 For Acute Leukemia

  Lead candidate in the MLLT1/3 programme, DBT 3757, is a differentiated investigational molecule designed to treat Acute Myelo...

January 08, 2026 | Thursday | News
Idorsia Initiates Phase 2 Trial of First-in-Class Oral CCR6 Antagonist in Psoriasis

The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indications ...

January 07, 2026 | Wednesday | News
MindRank Initiates Pivotal Phase III Trial for AI-Designed Oral GLP-1 Candidate MDR-001

MDR-001 progressed from program discovery to Phase III in just 4.5 years, much faster than traditional development cycles. Phase IIb data demonstrated...

January 07, 2026 | Wednesday | News
Hoth Therapeutics Files Two U.S. Provisional Patents to Establish Oncology-Focused Dermatology Platform

- Hoth Therapeutics (NASDAQ: HOTH), a clinical-stage biopharmaceutical company developing innovative therapies for underserved medical needs,  ...

January 06, 2026 | Tuesday | News
Kelun-Biotech’s TROP2 ADC sac-TMT Combo with Keytruda Granted Breakthrough Therapy Designation in China for First-Line NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK)  announced that its TROP2-directed antibody-drug ...

January 06, 2026 | Tuesday | News
Earendil Labs and Sanofi Forge Strategic Collaboration to Advance AI-Discovered Bispecific Therapies for Autoimmune Diseases

Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, announced a strategic collaboration with ...

January 06, 2026 | Tuesday | News
Axsome Biotherapeutics Stock Surges As FDA Grants Priority Review

Axsome Biotherapeutics announced that the US regulator has granted Priority Review to its investigational therapy for agitation associated with Alzheimer...

January 05, 2026 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close